A Phase 3 interventional study of Ixekizumab and Placebo in Psoriatic Arthritis, sponsored by Eli Lilly and Company. Completed at 106 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-15.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies in Arthritis, Psoriatic with a site in United States — 29 open to participants now, 59 under way, 20 of them phase 3. Arthritis, Psoriatic · United States.
Among the 193 studies in Arthritis, Psoriatic with a site in United States, this one is the 59th largest by enrollment of the 158 interventional ones that give a count, is one of 9 that started in 2015, is one of 71 in phase 3, and was the 69th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
Browse Arthritis, Psoriatic studies →29 of the 193 studies in Arthritis, Psoriatic with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–65
Medical College of Wisconsin · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 35 · Phase 3 73 · Phase 4 18
First in 1991; this study’s year is marked. 9 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 394 is above the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 237 across the 158 interventional studies, 325 across the 34 observational. Of the 128 that completed or were terminated, 79 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 193 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 8 studies filed under Arthritis, Psoriatic — fewer than ten, so there is no comparison to draw.
16 of the studies in Arthritis, Psoriatic with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641089Phase 3MoonLake Immunotherapeutics AGEvaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | 2027-01-04 |
| NCT06807424Phase 3Janssen Research & Development, LLCA Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis | 2027-02-10 |
| NCT06506916Phase 3UCB Biopharma SRLA Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis | 2027-03-09 |
| NCT06671483Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | 2027-05-18 |
| NCT06671496Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines | 2027-05-18 |
Add all 16 to your calendar (.ics) → With an account.
Among the 193 studies in Arthritis, Psoriatic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and long-term efficacy of ixekizumab compared to placebo in participants with active psoriatic arthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open-Label Treatment Period: Starting dose of 160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at baseline (week 0) followed by 80 mg given as one SC injection every two weeks (Q2W) from week 2 to randomization (week 36 to 64).
Drug: Ixekizumab
Participants completed open label and met criteria for randomization to the double-blind Withdrawal Period. Double-Blind Withdrawal Period: 80 mg ixekizumab given as one SC injection Q2W from randomization to week 104 (or, early termination or relapse).
Drug: Ixekizumab
Participants completed open label and met criteria for randomization to the double-blind Withdrawal Period. Double-Blind Withdrawal Period: Placebo given as one SC injection Q2W any time from randomization to week 104 (or, early termination or relapse)
Drug: Ixekizumab · Drug: Placebo
Participants completed open label but did not meet criteria for randomization to the double-blind Withdrawal Period. Participants continued to receive 80 mg given as one SC injection every two weeks during the double-blind withdrawal period.
Drug: Ixekizumab
Administered SC
Also known as: LY2439821
Administered SC
Double-Blind Withdrawal Period: Time to Relapse (No Longer Meeting Coates Criteria for Minimal Disease Activity [MDA])
Relapse is loss of MDA response. MDA is achieved if 5 of 7 outcome measures are fulfilled:TJC ≤1;SJC ≤1;psoriasis activity \& severity index(PASI total score) ≤1 or body surface area(BSA) ≤3;participant pain VAS score of ≤15;participant global disease activity VAS score of ≤20;HAQ-DI score ≤0.5;and tender entheseal points ≤1.Participants met the randomization criteria if they had MDA for 3 consecutive months over 4 consecutive visits.Time-to relapse was calculated in weeks as follows:((Date of Relapse) - Date of first injection of randomized study treatment in period 3)+1) divided by 7.If the date of first dose is missing,the date of randomization will be used.Participants completing Period 3 will be censored at date of completion(the date of the last scheduled visit in the period).Participants without a date of completion or discontinuation for Period 3 will be censored at latest non-missing date out of the following dates:date of last dose \& date of last attended visit in Period 3.
Time frame: Double Blind Randomization through Week 104 (or Early Termination or Relapse)
Double-Blind Withdrawal Period: Percentage of Participants Who Relapse in MDA
Relapsed participants are defined as participants no longer meeting Coates criteria for MDA. MDA is achieved if 5 of 7 outcome measures are fulfilled: TJC ≤1; SJC ≤1; psoriasis activity and severity index (PASI total score) ≤1 or body surface area (BSA) ≤3; participant pain VAS score of ≤15; participant global disease activity VAS score of ≤20; HAQ-DI score ≤0.5; and tender entheseal points ≤1.
Time frame: Double Blind Randomization through Week 104 (or Early Termination or Relapse)
Double-Blind Withdrawal Period: Time to Loss of Response in Each Individual Component of MDA: Tender Joint Count 68 (TJC)
TJC is the number of tender and painful joints determined for each participant by examination of 68 joints.TJC possible values range from 0 to 68. A lower TJC indicated less number of joints with tenderness. A higher TJC indicated more joint tenderness. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. Loss of Response = Not Meeting less than or equal to 1 TJC. Time to loss of response (in weeks) = (date of loss of response - date of first injection of randomized dose of study treatment in the Randomized Double-Blind Withdrawal Period + 1)/7.
Time frame: Double Blind Randomization through Week 104 (or Early Termination or Relapse)
Double-Blind Withdrawal Period: Time to Loss of Response in Each Individual Component of MDA: Swollen Joint Count 66 (SJC)
SJC is the number of swollen joints determined for each participant by examination of 66 joints. SJC possible values range from 0 to 66. A lower SJC indicated less joints with swelling. A higher SJC indicated more joints with swelling. Swelling was defined as palpable fluctuating synovitis of the joint. Loss of Response = Not Meeting less than or equal to 1 SJC. Time to loss of response (in weeks) = (date of loss of response - date of first injection of randomized dose of study treatment in the Randomized Double-Blind Withdrawal Period + 1)/7.
Time frame: Double Blind Randomization through Week 104 (or Early Termination or Relapse)
Double-Blind Withdrawal Period: Time to Loss of Response in Each Individual Component of MDA: Psoriasis Area and Severity Index (PASI)
The PASI is an index that combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Loss of Response = Not Meeting less than or equal to 1 PASI total score. Time to loss of response (in weeks) = (date of loss of response - date of first injection of randomized dose of study treatment in the Randomized Double-Blind Withdrawal Period + 1)/7.
Time frame: Double Blind Randomization through Week 104 (or Early Termination or Relapse)
Double-Blind Withdrawal Period: Time to Loss of Response in Each Individual Component of MDA: BSA
BSA is an investigator evaluated measure, where the percentage of involvement of psoriasis on each participant's BSA is assessed. BSA was measured on a continuous scale from 0% = no involvement to 100% = full involvement, where 1% corresponded to the size of the participant's handprint including the palm, fingers, and thumb. Loss of Response = Not meeting less than or equal to 3% BSA. Time to loss of response (in weeks) = (date of loss of response - date of first injection of randomized dose of study treatment in the Randomized Double-Blind Withdrawal Period + 1)/7.
Time frame: Double Blind Randomization through Week 104 (or Early Termination or Relapse)
Double-Blind Withdrawal Period: Time to Loss of Response in Each Individual Component of MDA: Pain Visual Analog Scale (VAS) Score
The pain VAS is an instrument used to measure a person's subjective quantitative evaluation of an item such as pain intensity. The VAS contains a continuous line between two endpoints whereby the respondent places a mark on the line to indicate his or her response The scale ranges from 0 (no pain) to 100 (unbearable pain). The scores were measured to the nearest millimeter from the left. Loss of Response = Not Meeting less than or equal to 15 Pain VAS. Time to loss of response (in weeks) = (date of loss of response - date of first injection of randomized dose of study treatment in the Randomized Double-Blind Withdrawal Period + 1)/7.
Time frame: Double Blind Randomization through Week 104 (or Early Termination or Relapse)
Double-Blind Withdrawal Period: Time to Loss of Response in Each Individual Component of MDA: Patients Global Assessment of Disease Activity (PatGA) Visual Analog Scale (VAS) Score
Participants scored their overall assessment of their psoriatic arthritis (PsA) activity on a 0 to 100 mm horizontal VAS. The scale ranged from 0 (no disease activity) to 100 (extremely active disease activity). The scores were measured to the nearest millimeter from the left. Loss of Response = Not Meeting less than or equal to 20 PatGA. Time to loss of response (in weeks) = (date of loss of response - date of first injection of randomized dose of study treatment in the Randomized Double-Blind Withdrawal Period + 1)/7.
Time frame: Double Blind Randomization through Week 104 (or Early Termination or Relapse)
Double-Blind Withdrawal Period: Time to Loss of Response in Each Individual Component of MDA: Health Assessment Questionnaire-Disability Index (HAQ-DI)
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (severe disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. Loss of Response = Not Meeting less than or equal to 0.5 HAQ-DI. Time to loss of response (in weeks) = (date of loss of response - date of first injection of randomized dose of study treatment in the Randomized Double-Blind Withdrawal Period + 1)/7.
Time frame: Double Blind Randomization through Week 104 (or Early Termination or Relapse)
Double-Blind Withdrawal Period: Time to Loss of Response in Each Individual Component of MDA: Tender Entheseal Points
Tender entheseal points was based on the assessment of the 18 entheseal points. Loss of Response = Not Meeting less than or equal to 1 Tender Entheseal Point. Time to loss of response (in weeks) = (date of loss of response - date of first injection of randomized dose of study treatment in the Randomized Double-Blind Withdrawal Period + 1)/7.
Time frame: Double Blind Randomization through Week 104 (or Early Termination or Relapse)
Open-Label Treatment Period: Time to Achieve Randomization Criteria (Meeting MDA for 3 Consecutive Months Over 4 Consecutive Visits)
Time to meeting MDA for 3 Consecutive Months Over 4 Consecutive Visits. Time to first response (in weeks) = \[(date of first response - date of first injection of study treatment in the Open-Label Treatment Period)+1\]/7. Open-Label Treatment Period ended at the time when a participant was randomized so the end time was not the same for all participants. Participants were randomized only if they met randomization criteria which was at anytime from week 36 to week 64.
Time frame: Open Label Baseline through Double-Blind Randomization (Week 36 to 64)
Double-Blind Withdrawal Period: Time to Re-Gain MDA Following Relapse in MDA
MDA is achieved if 5 of 7 outcome measures are fulfilled: TJC ≤1; SJC ≤1; psoriasis activity and severity index (PASI total score) ≤1 or BSA ≤3; participant pain VAS score of ≤15; participant global disease activity VAS score of ≤20; HAQ-DI score ≤0.5; and tender entheseal points ≤1. Time to first response (in weeks) = (date of first response - date of first injection of study treatment in the Relapse Period + 1)/7.
Time frame: Relapse in MDA After Double Blind Randomization through Week 104 (or Early Termination)
Double-Blind Withdrawal Period: Change From Baseline in Physical Functioning Assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI)
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (severe disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.Least Square (LS) mean calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment group, baseline measure, geographic region, cDMARD use, treatment week, baseline measure-by-treatment week interaction term, and treatment week-by-treatment interaction term as fixed factors. Participants were randomized only if they met randomization criteria which was at anytime from week 36 to week 64.
Time frame: Baseline, 40 Weeks from Double Blind Randomization (Week 36 to 64)
This study had four periods: Period 1: Screening period lasting from 4 to 30 days before Week 0, Period 2: Initial open-label treatment period from Week 0 up to Week 36, Period 3: randomized double-blind withdrawal period from Week 36 to week 104 (or, early termination or relapse) and Period 4: post treatment follow-up.
| Milestone | Ixekizumab Open Label | IXE80Q2W Non-randomized | Ixekizumab | Placebo | IXE80Q2W Post-Treatment Follow-up Period | Placebo Post-Treatment Follow-up Period |
|---|---|---|---|---|---|---|
| Started | 394 | 0 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 394 | 0 | 0 | 0 | 0 | 0 |
| Met randomization criteria | 158 | 0 | 0 | 0 | 0 | 0 |
| Non-randomized | 133 | 0 | 0 | 0 | 0 | 0 |
| Completed | 291 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 103 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 61 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 21 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 14 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: No pi available | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Ixekizumab Open Label | IXE80Q2W Non-randomized | Ixekizumab | Placebo | IXE80Q2W Post-Treatment Follow-up Period | Placebo Post-Treatment Follow-up Period |
|---|---|---|---|---|---|---|
| Started | 0 | 133 | 79 | 79 | 0 | 0 |
| Relapsed | 0 | 0 | 67 | 30 | 0 | 0 |
| Completed | 0 | 118 | 77 | 78 | 0 | 0 |
| Not completed | 0 | 15 | 2 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 4 | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 10 | 0 | 0 | 0 | 0 |
| Withdrew: Declined transfer to a different site | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Ixekizumab Open Label | IXE80Q2W Non-randomized | Ixekizumab | Placebo | IXE80Q2W Post-Treatment Follow-up Period | Placebo Post-Treatment Follow-up Period |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 355 | 12 |
| Completed | 0 | 0 | 0 | 0 | 347 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 8 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 7 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 | 0 |
Relapse is loss of MDA response. MDA is achieved if 5 of 7 outcome measures are fulfilled:TJC ≤1;SJC ≤1;psoriasis activity \& severity index(PASI total score) ≤1 or body surface area(BSA) ≤3;participant pain VAS score of ≤15;participant global disease activity VAS score of ≤20;HAQ-DI score ≤0.5;and tender entheseal points ≤1.Participants met the randomization criteria if they had MDA for 3 consecutive months over 4 consecutive visits.Time-to relapse was calculated in weeks as follows:((Date of Relapse) - Date of first injection of randomized study treatment in period 3)+1) divided by 7.If the date of first dose is missing,the date of randomization will be used.Participants completing Period 3 will be censored at date of completion(the date of the last scheduled visit in the period).Participants without a date of completion or discontinuation for Period 3 will be censored at latest non-missing date out of the following dates:date of last dose \& date of last attended visit in Period 3.
| Weeks | Ixekizumab | Placebo |
|---|---|---|
| Double-Blind Withdrawal Period: Time to Relapse (No Longer Meeting Coates Criteria for Minimal Disease Activity [MDA]) | NA (64.29 to NA) | 22.29 (16.14 to 28.29) |
Relapsed participants are defined as participants no longer meeting Coates criteria for MDA. MDA is achieved if 5 of 7 outcome measures are fulfilled: TJC ≤1; SJC ≤1; psoriasis activity and severity index (PASI total score) ≤1 or body surface area (BSA) ≤3; participant pain VAS score of ≤15; participant global disease activity VAS score of ≤20; HAQ-DI score ≤0.5; and tender entheseal points ≤1.
| percentage of participants | Ixekizumab | Placebo |
|---|---|---|
| Double-Blind Withdrawal Period: Percentage of Participants Who Relapse in MDA | 40.5 (29.7 to 51.3) | 86.1 (78.4 to 93.7) |
TJC is the number of tender and painful joints determined for each participant by examination of 68 joints.TJC possible values range from 0 to 68. A lower TJC indicated less number of joints with tenderness. A higher TJC indicated more joint tenderness. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. Loss of Response = Not Meeting less than or equal to 1 TJC. Time to loss of response (in weeks) = (date of loss of response - date of first injection of randomized dose of study treatment in the Randomized Double-Blind Withdrawal Period + 1)/7.
| weeks | Ixekizumab | Placebo |
|---|---|---|
| Double-Blind Withdrawal Period: Time to Loss of Response in Each Individual Component of MDA: Tender Joint Count 68 (TJC) | 64.29 (24.14 to NA) | 22.29 (12.29 to 28.71) |
SJC is the number of swollen joints determined for each participant by examination of 66 joints. SJC possible values range from 0 to 66. A lower SJC indicated less joints with swelling. A higher SJC indicated more joints with swelling. Swelling was defined as palpable fluctuating synovitis of the joint. Loss of Response = Not Meeting less than or equal to 1 SJC. Time to loss of response (in weeks) = (date of loss of response - date of first injection of randomized dose of study treatment in the Randomized Double-Blind Withdrawal Period + 1)/7.
| weeks | Ixekizumab | Placebo |
|---|---|---|
| Double-Blind Withdrawal Period: Time to Loss of Response in Each Individual Component of MDA: Swollen Joint Count 66 (SJC) | NA (NA to NA) | 28.71 (20.14 to NA) |
The PASI is an index that combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Loss of Response = Not Meeting less than or equal to 1 PASI total score. Time to loss of response (in weeks) = (date of loss of response - date of first injection of randomized dose of study treatment in the Randomized Double-Blind Withdrawal Period + 1)/7.
| weeks | Ixekizumab | Placebo |
|---|---|---|
| Double-Blind Withdrawal Period: Time to Loss of Response in Each Individual Component of MDA: Psoriasis Area and Severity Index (PASI) | NA (NA to NA) | 36.00 (24.14 to 48.14) |
BSA is an investigator evaluated measure, where the percentage of involvement of psoriasis on each participant's BSA is assessed. BSA was measured on a continuous scale from 0% = no involvement to 100% = full involvement, where 1% corresponded to the size of the participant's handprint including the palm, fingers, and thumb. Loss of Response = Not meeting less than or equal to 3% BSA. Time to loss of response (in weeks) = (date of loss of response - date of first injection of randomized dose of study treatment in the Randomized Double-Blind Withdrawal Period + 1)/7.
| weeks | Ixekizumab | Placebo |
|---|---|---|
| Double-Blind Withdrawal Period: Time to Loss of Response in Each Individual Component of MDA: BSA | NA (NA to NA) | NA (36.00 to NA) |
The pain VAS is an instrument used to measure a person's subjective quantitative evaluation of an item such as pain intensity. The VAS contains a continuous line between two endpoints whereby the respondent places a mark on the line to indicate his or her response The scale ranges from 0 (no pain) to 100 (unbearable pain). The scores were measured to the nearest millimeter from the left. Loss of Response = Not Meeting less than or equal to 15 Pain VAS. Time to loss of response (in weeks) = (date of loss of response - date of first injection of randomized dose of study treatment in the Randomized Double-Blind Withdrawal Period + 1)/7.
| weeks | Ixekizumab | Placebo |
|---|---|---|
| Double-Blind Withdrawal Period: Time to Loss of Response in Each Individual Component of MDA: Pain Visual Analog Scale (VAS) Score | NA (36.14 to NA) | 16.14 (12.14 to 22.71) |
Participants scored their overall assessment of their psoriatic arthritis (PsA) activity on a 0 to 100 mm horizontal VAS. The scale ranged from 0 (no disease activity) to 100 (extremely active disease activity). The scores were measured to the nearest millimeter from the left. Loss of Response = Not Meeting less than or equal to 20 PatGA. Time to loss of response (in weeks) = (date of loss of response - date of first injection of randomized dose of study treatment in the Randomized Double-Blind Withdrawal Period + 1)/7.
| weeks | Ixekizumab | Placebo |
|---|---|---|
| Double-Blind Withdrawal Period: Time to Loss of Response in Each Individual Component of MDA: Patients Global Assessment of Disease Activity (PatGA) Visual Analog Scale (VAS) Score | NA (NA to NA) | 20.57 (16.14 to 28.14) |
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (severe disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition. Loss of Response = Not Meeting less than or equal to 0.5 HAQ-DI. Time to loss of response (in weeks) = (date of loss of response - date of first injection of randomized dose of study treatment in the Randomized Double-Blind Withdrawal Period + 1)/7.
| weeks | Ixekizumab | Placebo |
|---|---|---|
| Double-Blind Withdrawal Period: Time to Loss of Response in Each Individual Component of MDA: Health Assessment Questionnaire-Disability Index (HAQ-DI) | NA (NA to NA) | NA (48.14 to NA) |
Tender entheseal points was based on the assessment of the 18 entheseal points. Loss of Response = Not Meeting less than or equal to 1 Tender Entheseal Point. Time to loss of response (in weeks) = (date of loss of response - date of first injection of randomized dose of study treatment in the Randomized Double-Blind Withdrawal Period + 1)/7.
| weeks | Ixekizumab | Placebo |
|---|---|---|
| Double-Blind Withdrawal Period: Time to Loss of Response in Each Individual Component of MDA: Tender Entheseal Points | NA (NA to NA) | NA (60.29 to NA) |
Time to meeting MDA for 3 Consecutive Months Over 4 Consecutive Visits. Time to first response (in weeks) = \[(date of first response - date of first injection of study treatment in the Open-Label Treatment Period)+1\]/7. Open-Label Treatment Period ended at the time when a participant was randomized so the end time was not the same for all participants. Participants were randomized only if they met randomization criteria which was at anytime from week 36 to week 64.
| weeks | Ixekizumab Open Label |
|---|---|
| Open-Label Treatment Period: Time to Achieve Randomization Criteria (Meeting MDA for 3 Consecutive Months Over 4 Consecutive Visits) | 64.43 (56.14 to NA) |
MDA is achieved if 5 of 7 outcome measures are fulfilled: TJC ≤1; SJC ≤1; psoriasis activity and severity index (PASI total score) ≤1 or BSA ≤3; participant pain VAS score of ≤15; participant global disease activity VAS score of ≤20; HAQ-DI score ≤0.5; and tender entheseal points ≤1. Time to first response (in weeks) = (date of first response - date of first injection of study treatment in the Relapse Period + 1)/7.
| weeks | Ixekizumab | Placebo |
|---|---|---|
| Double-Blind Withdrawal Period: Time to Re-Gain MDA Following Relapse in MDA | 4.71 (4.14 to 8.29) | 4.14 (4.14 to 4.29) |
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (severe disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.Least Square (LS) mean calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment group, baseline measure, geographic region, cDMARD use, treatment week, baseline measure-by-treatment week interaction term, and treatment week-by-treatment interaction term as fixed factors. Participants were randomized only if they met randomization criteria which was at anytime from week 36 to week 64.
| score on a scale | Ixekizumab | Placebo |
|---|---|---|
| Double-Blind Withdrawal Period: Change From Baseline in Physical Functioning Assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI) | -0.79 ± 0.06 | -0.67 ± 0.06 |
Collected over Up To 3 Years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ixekizumab Open Label | 2/394 (0.5%) | 20/394 (5.1%) | 143/394 (36.3%) |
| Ixekizumab | 0/79 (0%) | 1/79 (1.3%) | 25/79 (31.6%) |
| Placebo | 0/79 (0%) | 2/79 (2.5%) | 14/79 (17.7%) |
| IXE80Q2W Non-randomized Population to Withdrawal Period | 0/133 (0%) | 6/133 (4.5%) | 37/133 (27.8%) |
| IXE80Q2W Relapse Period | 0/97 (0%) | 1/97 (1%) | 30/97 (30.9%) |
| IXE80Q2W Post-Treatment Follow-up Period | 0/355 (0%) | 4/355 (1.1%) | 19/355 (5.4%) |
| Placebo Post-Treatment Follow-up Period | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) |
| Event | Ixekizumab Open Label | Ixekizumab | Placebo | IXE80Q2W Non-randomized Population to Withdrawal Period | IXE80Q2W Relapse Period | IXE80Q2W Post-Treatment Follow-up Period | Placebo Post-Treatment Follow-up Period |
|---|---|---|---|---|---|---|---|
| EndometriosisReproductive system and breast disorders | 0/212 | 1/32 | 0/39 | 0/78 | 0/53 | 0/195 | 0/6 |
| Ovarian cystReproductive system and breast disorders | 0/212 | 0/32 | 0/39 | 1/78 | 0/53 | 0/195 | 0/6 |
| Large intestine polypGastrointestinal disorders | 0/394 | 0/79 | 1/79 | 0/133 | 0/97 | 0/355 | 0/12 |
| Urinary tract infectionInfections and infestations | 0/394 | 0/79 | 1/79 | 0/133 | 0/97 | 0/355 | 0/12 |
| Upper limb fractureInjury, poisoning and procedural complications | 0/394 | 0/79 | 0/79 | 0/133 | 1/97 | 0/355 | 0/12 |
| CholelithiasisHepatobiliary disorders | 2/394 | 0/79 | 0/79 | 1/133 | 0/97 | 0/355 | 0/12 |
| BronchitisInfections and infestations | 2/394 | 0/79 | 0/79 | 1/133 | 0/97 | 0/355 | 0/12 |
| FallInjury, poisoning and procedural complications | 0/394 | 0/79 | 0/79 | 1/133 | 0/97 | 0/355 | 0/12 |
| Humerus fractureInjury, poisoning and procedural complications | 0/394 | 0/79 | 0/79 | 1/133 | 0/97 | 0/355 | 0/12 |
| Meniscus injuryInjury, poisoning and procedural complications | 1/394 | 0/79 | 0/79 | 1/133 | 0/97 | 0/355 | 0/12 |
| Event | Ixekizumab Open Label | Ixekizumab | Placebo | IXE80Q2W Non-randomized Population to Withdrawal Period | IXE80Q2W Relapse Period | IXE80Q2W Post-Treatment Follow-up Period | Placebo Post-Treatment Follow-up Period |
|---|---|---|---|---|---|---|---|
| Injection site reactionGeneral disorders | 59/394 | 1/79 | 0/79 | 2/133 | 7/97 | 0/355 | 0/12 |
| NasopharyngitisInfections and infestations | 34/394 | 11/79 | 4/79 | 19/133 | 13/97 | 2/355 | 0/12 |
| Upper respiratory tract infectionInfections and infestations | 49/394 | 9/79 | 4/79 | 12/133 | 9/97 | 8/355 | 0/12 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/212 | 2/32 | 0/39 | 0/78 | 0/53 | 0/195 | 0/6 |
| BronchitisInfections and infestations | 18/394 | 4/79 | 1/79 | 5/133 | 4/97 | 0/355 | 0/12 |
| Oral herpesInfections and infestations | 9/394 | 4/79 | 1/79 | 2/133 | 2/97 | 2/355 | 0/12 |
| Alanine aminotransferase increasedInvestigations | 11/394 | 4/79 | 1/79 | 2/133 | 1/97 | 3/355 | 0/12 |
| Aspartate aminotransferase increasedInvestigations | 6/394 | 4/79 | 1/79 | 1/133 | 1/97 | 2/355 | 0/12 |
| PsoriasisSkin and subcutaneous tissue disorders | 2/394 | 0/79 | 4/79 | 2/133 | 1/97 | 4/355 | 0/12 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Ixekizumab Open Label |
|---|---|
| Mean | 47.4 ± 11.40 |
| Sex: Female, Male(Participants) | Ixekizumab Open Label |
|---|---|
| Female | 212 |
| Male | 182 |
| Ethnicity (NIH/OMB)(Participants) | Ixekizumab Open Label |
|---|---|
| Hispanic or Latino | 16 |
| Not Hispanic or Latino | 330 |
| Unknown or Not Reported | 48 |
| Race (NIH/OMB)(Participants) | Ixekizumab Open Label |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 6 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 385 |
| More than one race | 2 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Ixekizumab Open Label |
|---|---|
| United States | 32 |
| Czechia | 90 |
| Ukraine | 43 |
| Poland | 60 |
| Mexico | 16 |
| South Africa | 26 |
| United Kingdom | 23 |
| Slovakia | 16 |
| Bulgaria | 20 |
| Estonia | 47 |
| Russia | 10 |
| Spain | 11 |
Showing the first 100 of 106 sites across 12 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Sep 2015 to primary completion in Oct 2018, 37 months.
Results were first posted in Nov 2019, 1 year after primary completion.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 37 months is above that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab